Dr. Peng Wang, a member of the China National “1000-Talents Program”, is currently Chief Scientific Officer of Simcere Pharmaceuticals Group, a leading Chinese pharmaceutical company headquartered in Nanjing, China (simcere.com; “SCR” at NYSE). Prior to joining Simcere, Dr. Wang was with WuXi PharmaTech (wuxiapptec.com; “WX” at NYSE), a leading pharmaceutical CRO in China, as Vice President of Discovery Biology in 2008-2009. Prior to joining WuXi PharmaTech, Dr. Wang worked on discovery through early clinical development for Schering-Plough in New Jersey, USA for 18 years. Dr. Wang has made significant contributions to discovery and early development of 16 drug candidates in US and China, and to establishment of several collaboration partnerships between Simcere and US companies. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J. etc. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, and his B.S. in Medicinal Chemistry from the China Pharmaceutical University.